170 related articles for article (PubMed ID: 2837073)
1. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice.
Matsumori A; Tomioka N; Kawai C
Am Heart J; 1988 Jun; 115(6):1229-32. PubMed ID: 2837073
[TBL] [Abstract][Full Text] [Related]
2. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D.
Kishimoto C; Crumpacker CS; Abelmann WH
Cardiovasc Res; 1988 Oct; 22(10):732-8. PubMed ID: 2855719
[TBL] [Abstract][Full Text] [Related]
3. Effects of granulocyte colony-stimulating factor upon coxsackievirus B3 myocarditis in mice.
Hiraoka Y; Kishimoto C; Takada H; Suzaki N; Shiraki K
Eur Heart J; 1995 Dec; 16(12):1900-6. PubMed ID: 8682024
[TBL] [Abstract][Full Text] [Related]
4. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model.
Matsumori A; Crumpacker CS; Abelmann WH
J Am Coll Cardiol; 1987 Jun; 9(6):1320-5. PubMed ID: 3034992
[TBL] [Abstract][Full Text] [Related]
5. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis.
Padalko E; Nuyens D; De Palma A; Verbeken E; Aerts JL; De Clercq E; Carmeliet P; Neyts J
Antimicrob Agents Chemother; 2004 Jan; 48(1):267-74. PubMed ID: 14693549
[TBL] [Abstract][Full Text] [Related]
6. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.
Dai K; Wang Y; Tai S; Ni H; Lian H; Yu Y; Liao W; Zheng C; Chen Q; Kuver A; Li J
Cardiovasc Ther; 2018 Dec; 36(6):e12477. PubMed ID: 30380183
[TBL] [Abstract][Full Text] [Related]
7. Role of oxygen derived free radicals in the pathogenesis of coxsackievirus B3 myocarditis in mice.
Hiraoka Y; Kishimoto C; Takada H; Kurokawa M; Ochiai H; Shiraki K; Sasayama S
Cardiovasc Res; 1993 Jun; 27(6):957-61. PubMed ID: 8221785
[TBL] [Abstract][Full Text] [Related]
8. Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage.
Kishimoto C; Kuroki Y; Hiraoka Y; Ochiai H; Kurokawa M; Sasayama S
Circulation; 1994 Jun; 89(6):2836-42. PubMed ID: 8205699
[TBL] [Abstract][Full Text] [Related]
9. Effects of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice.
Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
Cardiovasc Res; 1992 Oct; 26(10):956-61. PubMed ID: 1336713
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells.
Kishimoto C; Takada H; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
Cardiovasc Res; 1993 Feb; 27(2):243-8. PubMed ID: 8386064
[TBL] [Abstract][Full Text] [Related]
11. Detection of viral RNA in experimental coxsackievirus B3 myocarditis of mice using the polymerase chain reaction.
Okada I; Matsumori A; Kyu B
Int J Exp Pathol; 1992 Dec; 73(6):721-31. PubMed ID: 1337265
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis.
Kishimoto C; Thorp KA; Abelmann WH
Circulation; 1990 Sep; 82(3):982-9. PubMed ID: 2168299
[TBL] [Abstract][Full Text] [Related]
13. The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis.
Takada H; Kishimoto C; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
Heart Vessels; 1993; 8(2):59-66. PubMed ID: 8390975
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapy for prevention of acute coxsackievirus B3 myocarditis in mice.
Kishimoto C; Abelmann WH
Circulation; 1989 Jun; 79(6):1300-8. PubMed ID: 2541943
[TBL] [Abstract][Full Text] [Related]
15. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
[TBL] [Abstract][Full Text] [Related]
16. Colony-stimulating factors and coxackievirus B3 myocarditis in mice: macrophage colony-stimulating factor suppresses acute myocarditis with increasing interferon-alpha.
Hiraoka Y; Kishimoto C; Takada H; Suzaki N; Shiraki K
Am Heart J; 1995 Dec; 130(6):1259-64. PubMed ID: 7484779
[TBL] [Abstract][Full Text] [Related]
17. Coxsackievirus B3 myocarditis in C3H/HeJ mice: description of an inbred model and the effect of exercise on virulence.
Kiel RJ; Smith FE; Chason J; Khatib R; Reyes MP
Eur J Epidemiol; 1989 Sep; 5(3):348-50. PubMed ID: 2551723
[TBL] [Abstract][Full Text] [Related]
18. Successive infection of coxsackievirus B3 and encephalomyocarditis virus: an animal model of chronic myocarditis.
Okada I; Matsumori A; Tomioka N; Kawai C
J Pathol; 1992 Jul; 167(3):341-7. PubMed ID: 1325552
[TBL] [Abstract][Full Text] [Related]
19. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis.
Rezkalla S; Kloner RA; Khatib G; Smith FE; Khatib R
J Am Coll Cardiol; 1988 Aug; 12(2):412-4. PubMed ID: 2839568
[TBL] [Abstract][Full Text] [Related]
20. Persistence of replicating coxsackievirus B3 in the athymic murine heart is associated with development of myocarditic lesions.
Sato S; Tsutsumi R; Burke A; Carlson G; Porro V; Seko Y; Okumura K; Kawana R; Virmani R
J Gen Virol; 1994 Nov; 75 ( Pt 11)():2911-24. PubMed ID: 7964602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
